Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships

McGill University

$105,000.00

Mechanisms of Met Receptor Tyrosine Kinase Crosstalk in Tumourigenesis

FY 2008-09

Summary
Growth factor receptors initiate signals within the cell, directing it to grow and divide. Tight control of these receptors and the activating signals they transmit is key to maintaining normal cell behaviour. Unrestrained receptor activity leads to uncontrolled cell growth, characteristic of human cancers. There are multiple classes of receptors, and much of the research to date focused on each class individually, and how deregulation of one type of receptor promotes cancer progression. However, what is increasingly evident, is that different kinds of receptors can interact, cooperate, and coordinate with each other to drive tumour development. Recent work in cancer cells illustrate that drug treatment targeting one type of receptor, abolishing the growth signal sent in the cell, results in another receptor group compensating and raising its activity to restore the growth signal. This is one means through which drug resistance can occur. Our receptor of interest is the Met receptor, which is highly active in many types of cancer, including gastric, lung, and breast. I hypothesize that Met receptor signaling enhances the activity of other classes of receptors, creating a loaded arsenal of active receptors sending positive growth signals, thereby driving cancer initiation and progression. Preliminary data suggests that Met regulates the protein levels and activity of various receptors types through several mechanisms. I intend to elucidate the details of how Met signals may augment other receptor signaling in gastric cancer cells, as well as a drug-resistant lung cancer cell line, both of which possess active Met receptors. Existing drug treatments are meeting with limited success, due to the ability of tumour cells to subvert specific inhibitors by upregulating activity of another receptor. Therefore, it is important to identify the mechanisms responsible for drug resistance, such that more effective, multi-targeted therapies can be developed.
Program
Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
184545
Name
Lai Andrea
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Doctoral Research Awards - A
Projecttitle
Mechanisms of Met Receptor Tyrosine Kinase Crosstalk in Tumourigenesis
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$105,000
Cihrequipment2
$0
Programname2
Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships
Keyworddelim
Cbl E3 Ubiquitin Ligase; Cell Signaling; Cell/Tissue Culture; Egfr; Erbb3; Met; Receptor Cross Talk; Receptor Tyrosine Kinase; Tumourigenesis; Western Blot Analysis
Abstract
Growth factor receptors initiate signals within the cell, directing it to grow and divide. Tight control of these receptors and the activating signals they transmit is key to maintaining normal cell behaviour. Unrestrained receptor activity leads to uncontrolled cell growth, characteristic of human cancers. There are multiple classes of receptors, and much of the research to date focused on each class individually, and how deregulation of one type of receptor promotes cancer progression. However, what is increasingly evident, is that different kinds of receptors can interact, cooperate, and coordinate with each other to drive tumour development. Recent work in cancer cells illustrate that drug treatment targeting one type of receptor, abolishing the growth signal sent in the cell, results in another receptor group compensating and raising its activity to restore the growth signal. This is one means through which drug resistance can occur. Our receptor of interest is the Met receptor, which is highly active in many types of cancer, including gastric, lung, and breast. I hypothesize that Met receptor signaling enhances the activity of other classes of receptors, creating a loaded arsenal of active receptors sending positive growth signals, thereby driving cancer initiation and progression. Preliminary data suggests that Met regulates the protein levels and activity of various receptors types through several mechanisms. I intend to elucidate the details of how Met signals may augment other receptor signaling in gastric cancer cells, as well as a drug-resistant lung cancer cell line, both of which possess active Met receptors. Existing drug treatments are meeting with limited success, due to the ability of tumour cells to subvert specific inhibitors by upregulating activity of another receptor. Therefore, it is important to identify the mechanisms responsible for drug resistance, such that more effective, multi-targeted therapies can be developed.
Competitiondate
200810
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Lai, Andrea
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $105,000~ $0~
McGill University - $105,000 Grant (2008-09) | Canada Spends